ICER to Consider Aetion RWE in Revision of Hereditary Angioedema Therapy Report

ICER (the Institute for Clinical and Economic Review) has announced its decision to utilize RWE (real world evidence) data in its evaluation of three therapies (lanadelumab, Haegarda, and Cinryze) for use in preventing hereditary angioedema attacks. It will revise its 2018 report based on these data from Aetion. This could signify more widespread use of RWD and RWE in the context of ICER’s reports.

According to ICER’s Dr. Jon Campbell, “By defining the baseline demographics and utilization characteristics of patients who start HAE prophylaxis, evaluating HAE attack rates before initiation of prophylaxis, and updating our health cost assumptions accordingly, ICER aims to further clarify the overall value of these HAE therapies in real-world settings. We appreciate Aetion’s continued partnership as we work together to set new standards for how decision-grade RWE can be appropriately applied alongside high-quality clinical trial data to better inform the consequential decisions that biopharma manufacturers, insurers, and other stakeholders make every single day around drug pricing and patient access.” Read more here.

(Source: ICER, 4/12/21)